Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
258 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07314164 | Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment | recruiting | — | 150 | IpsenINDUSTRY | 2 | Sep 1, 2026 | clinicaltrials |
| NCT07611110 | AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)(VECTRA-01) | recruiting | Phase 3 | 670 | AstraZenecaINDUSTRY | 20 | Aug 26, 2026 | clinicaltrials |
| NCT06765109 | Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC(ALKAZAR) | recruiting | Phase 3 | 450 | Nuvalent Inc.INDUSTRY | 29 | Aug 25, 2026 | clinicaltrials |
| NCT07785154 | A Registry-study of ELZONRIS in Participants With BPDCN | recruiting | — | 80 | Stemline Therapeutics, Inc.INDUSTRY | 4 | Aug 25, 2026 | clinicaltrials |
| NCT05020236 | A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments(MAGNETISMM-5) | recruiting | Phase 3 | 893 | PfizerINDUSTRY | 26 | Aug 24, 2026 | clinicaltrials |
| NCT05183035 | Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | recruiting | Phase 3 | 130 | PedAL BCU, LLCOTHER | 20 | Aug 24, 2026 | clinicaltrials |
| NCT06382948 | Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.(ADELA) | recruiting | Phase 3 | 300 | MedSIROTHER | 9 | Aug 24, 2026 | clinicaltrials |
| NCT07129993 | Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma | recruiting | Phase 2 / Phase 3 | 630 | Daiichi SankyoINDUSTRY | 7 | Aug 20, 2026 | clinicaltrials |
| NCT05774951 | A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy(CAMBRIA-1) | recruiting | Phase 3 | 4,300 | AstraZenecaINDUSTRY | 39 | Aug 19, 2026 | clinicaltrials |
| NCT05945732 | DESTINY Breast Respond HER2-(Ultra)Low Europe | recruiting | — | 2,295 | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyINDUSTRY | 10 | Aug 19, 2026 | clinicaltrials |
| NCT06467357 | Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer(DESTINY-BTC01) | recruiting | Phase 3 | 620 | AstraZenecaINDUSTRY | 27 | Aug 19, 2026 | clinicaltrials |
| NCT07084558 | ABCSG 61 / TEODOR : Neoadjuvant TrEatment Optimization Driven by Circulating Tumor DNA and endOcrine Responsiveness(TEODOR) | recruiting | N/A | 350 | Austrian Breast & Colorectal Cancer Study GroupNETWORK | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05254743 | A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)(BRUIN-CLL-314) | recruiting | Phase 3 | 737 | Loxo Oncology, Inc.INDUSTRY | 23 | Aug 17, 2026 | clinicaltrials |
| NCT06149286 | A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma(OLYMPIA-5) | recruiting | Phase 3 | 580 | Regeneron PharmaceuticalsINDUSTRY | 18 | Aug 14, 2026 | clinicaltrials |
| NCT07612917 | Brain Connectivity Changes in Glioma Patients During Treatment(GliRecon) | recruiting | — | 20 | Johannes Kepler University of LinzOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT02300766 | Cerebellar Mutism Syndrome Study | recruiting | — | 2,000 | Rigshospitalet, DenmarkOTHER | 14 | Aug 12, 2026 | clinicaltrials |
| NCT05916313 | A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3 | recruiting | Phase 1 | 20 | Boehringer IngelheimINDUSTRY | 6 | Aug 11, 2026 | clinicaltrials |
| NCT07100730 | Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma(IPAX BrIGHT) | recruiting | Phase 3 | 50 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 4 | Aug 11, 2026 | clinicaltrials |
| NCT06731478 | Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer | recruiting | Phase 3 | 726 | Daiichi SankyoINDUSTRY | 26 | Aug 10, 2026 | clinicaltrials |
| NCT06926868 | A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) | recruiting | Phase 2 / Phase 3 | 600 | Bristol-Myers SquibbINDUSTRY | 28 | Aug 10, 2026 | clinicaltrials |
| NCT07140172 | Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery(OPBC-10/ NOAX) | recruiting | N/A | 1,060 | University Hospital, Basel, SwitzerlandOTHER | 11 | Aug 7, 2026 | clinicaltrials |
| NCT06203210 | A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer(IDeate-Lung02) | recruiting | Phase 3 | 540 | Daiichi SankyoINDUSTRY | 23 | Aug 6, 2026 | clinicaltrials |
| NCT07024706 | Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab(MAVRiC) | recruiting | Phase 2 | 80 | AstraZenecaINDUSTRY | 8 | Aug 6, 2026 | clinicaltrials |
| NCT05176483 | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors(STELLAR-002) | recruiting | Phase 1 | 1,394 | ExelixisINDUSTRY | 13 | Aug 5, 2026 | clinicaltrials |
| NCT07227402 | A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)(LITESPARK-033) | recruiting | Phase 3 | 904 | Merck Sharp & Dohme LLCINDUSTRY | 23 | Aug 3, 2026 | clinicaltrials |
| NCT06486883 | Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype(PONTIAC) | recruiting | Phase 2 | 200 | MedSIROTHER | 10 | Jul 30, 2026 | clinicaltrials |
| NCT06830720 | A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence(CAROLEEN) | recruiting | — | 3,250 | Novartis PharmaceuticalsINDUSTRY | 2 | Jul 30, 2026 | clinicaltrials |
| NCT06675604 | LEOPARD Training and Validation Data Collection Study(LEOPARD TVDCS) | recruiting | — | 4,500 | Assistance Publique - Hôpitaux de ParisOTHER | 7 | Jul 29, 2026 | clinicaltrials |
| NCT07044336 | Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | recruiting | Phase 3 | 800 | AstraZenecaINDUSTRY | 28 | Jul 29, 2026 | clinicaltrials |
| NCT07106762 | Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy | recruiting | Phase 2 / Phase 3 | 470 | Bristol-Myers SquibbINDUSTRY | 22 | Jul 29, 2026 | clinicaltrials |
| NCT05460000 | A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy(N-Plus) | recruiting | Phase 2 | 640 | North Eastern German Society of Gynaecological OncologyOTHER | 6 | Jul 27, 2026 | clinicaltrials |
| NCT05253651 | A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer(MOUNTAINEER-03) | recruiting | Phase 3 | 400 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 25 | Jul 22, 2026 | clinicaltrials |
| NCT06788990 | FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC(FORTIFI-HN01) | recruiting | Phase 2 / Phase 3 | 650 | Bicara TherapeuticsINDUSTRY | 26 | Jul 17, 2026 | clinicaltrials |
| NCT05327894 | Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia(Interfant-21) | recruiting | Phase 3 | 160 | Princess Maxima Center for Pediatric OncologyOTHER | 24 | Jul 10, 2026 | clinicaltrials |
| NCT04877522 | Asciminib Roll-over Study | recruiting | Phase 4 | 347 | Novartis PharmaceuticalsINDUSTRY | 29 | Jul 6, 2026 | clinicaltrials |
| NCT06819007 | Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)(DO-01) | recruiting | Phase 3 | 582 | Daiichi SankyoINDUSTRY | 25 | Jul 2, 2026 | clinicaltrials |
| NCT06162221 | Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC | recruiting | Phase 1 / Phase 2 | 616 | Revolution Medicines, Inc.INDUSTRY | 13 | Jun 30, 2026 | clinicaltrials |
| NCT06216301 | LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC(LUNAR-2) | recruiting | Phase 3 | 734 | NovoCure GmbHINDUSTRY | 16 | Jun 25, 2026 | clinicaltrials |
| NCT02834884 | SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access(SPECTA) | recruiting | — | 4,975 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 20 | Jun 24, 2026 | clinicaltrials |
| NCT04641247 | A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study | recruiting | Phase 2 | 37 | GlaxoSmithKlineINDUSTRY | 8 | Jun 24, 2026 | clinicaltrials |
| NCT06326190 | 177Lu-DOTATATE for Recurrent Meningioma(LUMEN-1) | recruiting | Phase 2 | 136 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | Jun 15, 2026 | clinicaltrials |
| NCT04844866 | Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients(DALY 2-EU) | recruiting | Phase 2 | 213 | Miltenyi Biomedicine GmbHINDUSTRY | 14 | Jun 10, 2026 | clinicaltrials |
| NCT06579911 | Combining High-frequency Micro-ultrasound and Multiparametric MRI Target Biopsy for Detecting Prostate Cancer(Biopsy29) | recruiting | N/A | 400 | Salzburger LandesklinikenOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07267000 | EXERCISE AND THE IMMUNE RESPONSE IN LUNG CANCER(ImmuEX) | recruiting | N/A | 50 | Medical University of GrazOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07635732 | Urinary Microbiome as a Biomarker for Melanoma Diagnosis and Response Prediction to Systemic Tumour Therapy | recruiting | — | 50 | Medical University of GrazOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT05904119 | Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study(LEGATO) | recruiting | Phase 3 | 411 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 11 | Jun 8, 2026 | clinicaltrials |
| NCT05243797 | Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation(MajesTEC-4) | recruiting | Phase 3 | 1,594 | European Myeloma Network B.V.NETWORK | 25 | Jun 4, 2026 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials